Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CAEL-101 plus standard plasma cell dyscrasia therapy versus placebo plus standard therapy in treatment-naive Mayo stage IIIa AL amyloidosis
MOH_2021-05-12_009869Phase 3Recruiting
- Sponsor
- Caelum Biosciences
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing CAEL-101 + standard plasma cell dyscrasia therapy with Placebo + standard plasma cell dyscrasia therapy (2 arms). Primary endpoints: Overall survival and Safety and tolerability. Started Mar 2021; status: recruiting.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2021-05-12_009869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-12_009869.